WP
NRIX icon

Woodline Partners’s Nurix Therapeutics NRIX Stock Holding History

Woodline Partners’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.8M Buy
1,064,006
+138,562
+15% +$2.36M 0.08% 313
2026
Q1 		$14.3M Hold
925,444
– – 0.05% 420
2025
Q4 		$17.6M Buy
925,444
+848,900
+1,109% +$12.2M 0.07% 340
2025
Q3 		$707K Sell
76,544
-23,727
-24% -$246K ﹤0.01% 821
2025
Q2 		$1.14M Buy
100,271
+67
+0.1% +$724 0.01% 791
2025
Q1 		$1.19M Sell
100,204
-238,258
-70% -$3.98M 0.01% 746
2024
Q4 		$6.38M Buy
338,462
+1,583
+0.5% +$36.3K 0.04% 436
2024
Q3 		$7.57M Buy
336,879
+34,992
+12% +$793K 0.06% 337
2024
Q2 		$6.3M Buy
+301,887
New +$4.7M 0.06% 314
2022
Q2 		– Sell
-219,281
Closed -$3.07M – 859
2022
Q1 		$3.07M Sell
219,281
-373,660
-63% -$6.63M 0.05% 309
2021
Q4 		$17.2M Buy
592,941
+455,540
+332% +$13.8M 0.25% 120
2021
Q3 		$4.12M Buy
+137,401
New +$4.24M 0.07% 285
2021
Q1 		– Sell
-161,211
Closed -$5.3M – 459
2020
Q4 		$5.3M Buy
161,211
+17,124
+12% +$567K 0.14% 154
2020
Q3 		$5.03M Buy
+144,087
New +$3.63M 0.16% 128

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Woodline Partners's NRIX Position: Q2 2026 in Review

Woodline Partners increased its Nurix Therapeutics (NRIX) stake by 15% in Q2 2026, buying an estimated $2.36M and bringing the position to 1,064,006 shares worth $25.8M. The position accounts for 0.08% of the portfolio, ranked #313.

Woodline Partners first reported a position in NRIX in Q3 2020 and has held it in 14 quarters since. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Woodline Partners held 1,064,006 shares of Nurix Therapeutics worth $25.8M as of Q2 2026.
  • Woodline Partners bought 138,562 Nurix Therapeutics shares in Q2 2026, an estimated $2.36M.
  • Nurix Therapeutics made up 0.08% of Woodline Partners's portfolio in Q2 2026, its #313 holding.
  • Woodline Partners first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 14 quarters since.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.